DIMA Biotechnology

DIMA Biotechnology specialises in the development of recombinant proteins, monoclonal antibodies and antibody engineering technologies for drug discovery and life science research. The company focuses particularly on challenging drug targets, including membrane proteins, using mammalian cell expression systems designed to generate proteins with native post-translational modifications, solubility and structural integrity. Its technology platforms support antibody discovery, therapeutic antibody optimisation and target validation, enabling researchers to investigate biologically relevant proteins and accelerate early-stage research and development programmes across immunology, oncology and other therapeutic areas.

The company’s portfolio includes over 2000 recombinant extracellular domain and full-length membrane proteins produced using Membrane Nanoparticle (MNP), Virus-Like Particle (VLP), Exosome (EXO), detergent-based and synthetic nanodisc platforms. DIMA also offers monoclonal antibody development services through its Single B Cell mAb Development Platform, which enables direct isolation and sequencing of antigen-specific B cells from immunised animals. Its proprietary DiLibrary™ platform supports antibody humanisation, chimerisation, affinity maturation and developability assessment using mammalian cell display technology. In addition, DIMA provides custom protein production, SPR analysis, CAR-T evaluation services and access to pre-sequenced antibody libraries for screening and licensing applications.

Europa Biosite subsidiaries distribute DIMA Biotechnology products in Austria, Belgium, Canada, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Latvia, Lithuania, Luxemburg, Netherlands, Norway, Sweden, Switzerland, United Kingdom and the USA.